Navigation Links
Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
Date:10/22/2008

PITTSBURGH, Oct. 22 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today confirmed that the company and its subsidiary, Mylan Pharmaceuticals Inc., have been sued by Novartis in connection with Fluvastatin Capsules USP, 20 mg (base) and 40 mg (base), the generic version of Novartis' Lescol(R) Capsules.

Mylan believes it is the first company to file a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification for the product. The company filed an ANDA with the U.S. Food and Drug Administration (FDA) in June. Novartis filed a lawsuit Oct. 10 in the U.S. District Court for the District of New Jersey alleging infringement of U.S. Patent No. 5,354,772.

Fluvastatin Capsules, used in the treatment of high cholesterol, had approximately $60 million in sales for the twelve months ending June 30, 2008, according to IMS Health.

Currently, Mylan has 108 ANDAs pending FDA approval, 22 of which are potential first-to-file opportunities.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit http://www.mylan.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first to file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
2. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
3. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
4. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
7. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
8. Mylan to Host Investor Day on October 3, 2007
9. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
10. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
11. Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... Francisco, CA (PRWEB) , ... February 04, 2016 ... ... of enterprise talent development and compliance training, today announced an interactive FDA ... Morf Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course on ...
(Date:2/4/2016)... 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... Edward Lanphier , Sangamo,s president and chief executive ... Sangamo,s ZFP Therapeutic ® development programs and an ... ET on Thursday, February 11, 2016, at the Leerink ... conference is being held in New York ...
Breaking Biology Technology:
(Date:1/25/2016)... --  Unisys Corporation (NYSE: UIS ) today announced the ... Airport, New York City , to help ... enter the United States using passports that ... testing of the system at Dulles last year. The system ... January 2016. --> pilot testing of the system ...
(Date:1/20/2016)... , Jan. 20, 2016 A market ... to directly benefit from the explosion in genomics knowledge. ... Howe Sound Research. A range of dynamic trends are ... - personalized medicine - pharmacogenomics - pathogen evolution ... with large markets - greater understanding of the role ...
(Date:1/13/2016)... --> --> ... report titled - Biometric Sensors Market - Global Industry Analysis, ... to the report, the global biometric sensors market was valued at ... US$1,625.8 mn by 2023, expanding at a CAGR of ... the biometric sensors market is expected to reach 1,799.6 ...
Breaking Biology News(10 mins):